Drug Profile


Alternative Names: BM 202; Vibrilase; Vibriolysin topical

Latest Information Update: 01 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator W.R. Grace
  • Class Peptide hydrolases; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Burns

Most Recent Events

  • 01 Jun 2005 Vibriolysin is available for licensing (
  • 30 Aug 2004 A study has been added to the adverse events and Skin disorders therapeutic trials sections
  • 29 Jun 2004 BioMarin has completed enrolment in a phase Ib study for Burns in the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top